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Background and aim: Dementia is a condition which results in high cost of care, a significant 
proportion of which is the cost associated with informal care. In previous studies, informal 
caregiving has been challenging to assess due to difficulties in estimating true time spent on 
caregiving work and how to value caregivers’ time. The aim of this study was to compare the costs 
of dementia among patients living alone and among those living with a caregiver to show the 
monetary value of informal caregiving from a societal perspective.  
Methods:   Data from our four dementia trials using the same measures were combined, allowing 
604 participants to be included. Participants were followed up for two years or until death for their 
use of health and social services. Use of all services was retrieved from medical/social records. We 
also included the costs of lost productivity of those caregivers who were not retired. 
Results:  The total mean cost of services and lost productivity was 22068 €/person-year (pyrs). 
Participants living alone had a mean cost of 45156 €/pyrs, whereas those living with a spouse had a 
mean cost of 16416 €/pyrs (mean cost ratio 2.99, 95% CI 2.64 to 3.39). Participants living alone 
and having <15 MMSE points had higher costs than people with dementia in institutional care. 
Key conclusions:  Detailed data of service use and characteristics of people with dementia showed 
that from a societal perspective living alone is a very strong determinant of service use in dementia. 





There is a large cost associated with the care of people with dementia (PWD) due to the extensive 
needs for personal care, long-term care and various health care services [1,2]. 
The yearly costs of patient care have varied greatly [3] depending on characteristics of the patients, 
country, how formal and informal costs have been taken into account and follow-up times [4]. 
Whereas a large proportion of cost studies have been dementia drug trials, the target population has 
mainly included community-dwelling people with mild-moderate dementia [5]. Of them, only a 
small proportion enters nursing homes, which is one of the main cost drivers in dementia [6].  
Some studies present only direct costs including social care costs (home care, day care, nursing 
home) and medical care costs (hospitals, outpatient care, drug use) [6]. Several studies include also 
hours of informal care in their direct costs which are counted as either replacement costs (the value 
of equivalent service purchased from the market) or opportunity costs (the value of the caregiver's 
time in its best alternative use) [6,7]. However, quantification and costing of informal care are 
extremely challenging [5]. In many studies, the estimated time for caregiving has exceeded that of 
total time available because of multitasking [7] or difficulties in estimating the time spent on 
supervision [8].  
Studies have also presented indirect costs which include costs of informal care as costs of lost 
productivity of working-aged individuals (either caregivers or PWD) [6]. In most studies, informal 
costs have comprised the largest proportion of total care [5,7,8]. 
To sum up earlier studies have presented a wide range of estimates of costs of informal care using 
various approaches to evaluate the caregiving work. This study aims to compare the total costs of 
PWD living alone with respective PWD living with a caregiver. This enables us to also estimate the 
monetary value of work of those caregivers living with PWD. We use the detailed social and 
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medical care costs from our previous four non-pharmacological trials following PWD for two years 






Data on participants from our four earlier dementia trials using the same measures were combined: 
(I) Case coordinator trial (N=125) [9], (II) FINALEX exercise trial (N=210) [10], (III) Self-
management trial (N=134) [11] and (IV) FINCOG cognitive training trial (N=147) [12]. All trials 
received ethical permission from Helsinki University Hospital. Briefly, all trials had a non-
pharmacological intervention to be tested among PWD I: case coordinator tailored services and 
giving support to dementia families for two years, II: exercise intervention supervised by a 
physiotherapist twice a week for one year either in the gym or at the participant’s home, III: a 
group-based self-management group rehabilitation for people recently diagnosed with dementia and 
concurrently for their spouses, IV: supervised cognitive training twice a week for three months in a 
day care center for people with mild-moderate dementia. The four trials included a range of PWD 
from mild to severe stages, living alone or with a spouse or another caregiver. All participants in 
these studies were followed up prospectively for two years. Although some of these trials had 
positive effects on postponing institutional care [9] and improving physical or cognitive functioning 
[10,11], all interventions were cost-neutral when the intervention and control arms were compared. 
Thus, they provide a dataset to explore costs of health and social services. The intervention costs are 
not taken into account in the present study. 
Characteristics 
All trials used the same measures. The demographics were recorded for both PWD and their 
possible caregivers. If the caregiver was not available for the person with dementia, the information 
was inquired from the participant's closest relative or from a home or day care nurse. Living alone 
or with a spouse or with another close person was retrieved from central registers.  
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The participants with dementia were assessed with the Clinical Dementia Rating (CDR) scale [13] 
and the Mini Mental State Examination (MMSE) [14] for the severity of dementia. The item 
"personal care" in CDR was used to evaluate physical functioning [13]. All medical diagnoses and 
regularly used medications were retrieved from medical records. Charlson comorbidity index was 
constructed [15]. The use of antidementia medications was recorded (N06DA02 donepezil, 
N06DA03 rivastigmine, N06DA05 galantamine, N06DX01 memantine). In trials I and II, the 
caregiving burden was assessed with the Zarit burden interview, with 60 points or over considered 
as severe burden [16]. In trials III and IV, the caregivers were assessed with RAND-36 [17], and the 
item:  “..for the past four weeks "Did you feel worn out?" and the responses "All the time" or "Most 
of the time" were considered to denote severe burden.  
Costs 
Participants were followed up prospectively for two years or until death regarding their use of 
health and social services. Service use was retrieved from medical/social records. Health care costs 
included the use of subacute rehabilitation and acute specialised hospitals, emergency department 
and ambulatory care visits, hospital-at-home visits, primary health care visits (general practitioner, 
nurse, physiotherapist, social worker) and home visits by doctors, dementia nurses or home care 
nurses. Social care included home care, day care, respite care and nursing home days. In Finland, all 
community care services and utilisation of hospitals are recorded in central registers and medical 
and social records, which were accessed after obtaining participants’ consent. Service costs were 
determined at their mean unit costs according to the national cost registers in 2011 [18], with an 
appropriate correction for inflation rate. The costs of antidementia medications were retrieved from 
the Finnish drug database. All costs were calculated in Euros (€) and transformed to 2019 rates. 
The indirect costs were evaluated as costs of lost productivity of those of working age for both 
participants with dementia and caregivers who were younger than the average retirement age in 
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Finland (men 61.6 years, women 60.9 years) [19].  The cost of lost productivity was valued as the 
average wage in Finland (men 19.21 €/h, women 16.45 €/h) [20], and we used the average 
ADL/IADL caregiving time (1.9 h/day) for people with dementia in previous studies [6].  
We aimed to estimate the real value of the work of informal caregivers living with the person with 
dementia. Therefore, we excluded replacement costs and opportunity costs which are actually 
important monetary savings that informal caregivers’ work confers to society. Our cost calculation 
is in line with the principles presented by Wimo et al. [6]. 
Costs are presented in our study as total costs and as the mean costs per person year.  
Statistical analyses 
Baseline characteristics between groups were compared using t-tests (for continuous variables) or 
Chi-square tests (for categorical variables). The bootstrap-type t-test was used when the theoretical 
distribution of the test statistics was unknown or in case of violation of the assumptions (e.g. non-
normality). The visits to professionals of health and social care were analysed by using Poisson’s 
model and reported as mean (SE) days or visits and incidence rate ratios (IRRs) with 95% 
confidence intervals (CIs). Cost analyses were performed using bootstrap-type generalised linear 
models with appropriate distribution and link function (10000 replications). The variance function 
was selected based on the Park test and Akaike’s information criterion. The models included age 
and sex as covariates. The normality of variables was evaluated graphically and by using the 
Shapiro–Wilk W test. Stata 16.0 (StataCorp LP; College Station, Texas, USA) statistical package 





The participants living alone were younger, more often females and less educated than those living 
with a caregiver. They had a milder stage of dementia and needed less assistance in their personal 
care than those living with a caregiver. They used more often memantine and less often 
cholinesterase inhibitors (ChEIs) than those living with a caregiver. (Table 1). 
Older age, female sex and severity of dementia increased total costs of care (data not shown). 
Living alone was a very strong determinant of costs of services. Those living alone used 
significantly more home care services, day care, subacute hospital care and institutional care than 
those living with a caregiver. Those living alone used less respite care, specialised care, emergency 
care and various primary care services, except for family physician’s home visits. The lost 
productivity costs were higher in the group of PWD living alone than among those living with a 
caregiver (3883 €/pyrs vs. 193 €/pyrs). Those living alone had a caregiver of working age, whereas 
most of the caregivers living with a person with dementia were aged spouses (Table 2). 
The mean costs of services were 49156 €/pyrs among those living alone, whereas the respective 
figure was 16416 € for those living with a caregiver (mean cost ratio 2.99; 95%CI 2.64 to 3.39). 
Adjusting for age and sex (mean cost ratio 2.95; 95%CI 2.55 to 3.35) did not change this difference 
between the costs. We made further adjustments for age, sex and CDR, or for age, sex and Charlson 
comorbidity index, but these yielded similar results (data not shown).  
The severity of dementia was also a strong determinant in the use of services. The costs increased 
linearly with severity of dementia (Figure 1). At a moderate stage of severity (CDR2 or MMSE <15 
points), the costs of PWD living alone exceeded the corresponding costs of those living in 
permanent institutional care (mean costs in Finland 51465€/year). There were no PWD living alone 
at home and having <10 MMSE points, whereas many caregivers lived with a person with dementia 
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with very low MMSE points. Participants living with a spouse had lower costs than PWD in 





Living alone is a strong determinant of costs of dementia. The mean costs for services together with 
those of lost productivity among people with dementia living alone is 49156 €/pyrs, whereas the 
respective figure among those living with a caregiver is 16416 €/pyrs. Even after various 
adjustments, the costs are nearly three times higher among those living alone than among those 
living with a caregiver. The work that caregivers living with PWD do has a high monetary value, 
generating considerable savings for society.  
Strengths of this study include detailed data and validated measures on the demographics, 
functioning, cognition, caregiver status and services used. Finnish medical and social registers 
include very detailed and complete data on use of services of PWD. We also included lost 
productivity costs to show the true value of caregiving from a societal perspective. The follow-up of 
two years is exceptionally long and allows us to evaluate the true course of dementia, including 
those entering permanent institutional care.  
Limitations of the study include the data being retrieved from randomised controlled trials. Trials 
have exclusion criteria and there is a bias towards recruiting younger and healthier participants than 
in the normal service system. However, these four trials testing non-pharmacological interventions 
are much more pragmatic than many previous antidementia drug trials, which have been a major 
source for investigating costs of dementia [5,8,21]. Our participants were older with more 
comorbidities than participants in earlier studies [1,5,7,8,21-25], which also included a wide range 
of people having very mild to very severe dementia. However, people participating in our trials 
have less severe dementia and use more often antidementia medications than those in large 
epidemiological studies [1,25-27]. Furthermore, the caregivers in our study are younger and better 
educated than those in Finnish epidemiological study [26]. In addition, the health and social care 
systems as well as the local policies vary from country to country and the service system has also 
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developed in Finland over the years from our first study. This makes the comparison to other 
contexts challenging although the components of services are similar to those in the Swedish system 
[6].   
In line with a Swedish study, people living alone used less antidementia medications than those 
living with a caregiver [28]. In Finland memantine is recommended at moderate-severe stage of 
dementia. It seems that CHEIs are stopped and memantine started at earlier stage for those people 
with dementia living alone than those living with a caregiver.  
Another limitation is that the caregiving time of 1.9 h/day is a coarse estimate of the true caregiving 
time based on a previous study [6]. In our first trial “Caregiving as collaboration”, we found that it 
is impossible for caregivers to evaluate how much time they spend on caregiving and how much on 
regular housework. This has also been noted in an earlier study [6]. However, if the true caregiving 
time is higher – as our participants had more severe dementia than in previous studies – the 
difference between the costs of those living alone compared with those living with a caregiver 
would be even higher. This is due to the fact that those living alone had more caregivers of working 
age, thus indicating more lost productivity. Therefore, societal savings from caregiving might be an 
underestimation of the true value. 
Our estimate of yearly costs of care and services for dementia (22068 €/pyrs) is comparable to 
figures presented elsewhere [2,3,4,21]. The unit costs of services used in the present study are 
similar to those presented in Sweden [6].  However, compared with earlier studies medication costs 
today are very low due to the inexpensive generic antidementia medications.  
The difference in costs between those living with a caregiver (16416 €/pyrs) and those living alone 
(46156 €/pyrs) was quite large. To our knowledge, there are no earlier studies comparing these 
groups of PWD. It has been noted before, however, that a caregiver’s closeness to the person with 
dementia reduces total care costs [29]. Those living alone use an exceptional amount of home care 
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services, day care and subacute hospitals. They are also admitted earlier to nursing homes, resulting 
in higher use of institutional care. Our study clearly shows that caregivers’ work has a very high 
monetary value to societies.  The proportion of informal care costs of the total care costs has varied 
greatly (8-78%) in previous studies [3].  
The care for PWD has shifted from society to informal caregiving. The relative number of nursing 
home beds is decreasing in many European countries [6,30]. It has been argued that care at home is 
cheaper than in a nursing home. This is, however, only true among those people with dementia who 
live with their caregiver. Our study suggests that care for a person with dementia living alone at 
home may be more expensive than care for a person with dementia in a nursing home. This applies 
when MMSE points are lower than 15, ie at a moderate stage of dementia. This should be taken into 
account when planning services for PWD.  
Conclusions 
Detailed data on service use and characteristics of PWD showed that informal caregivers do 
invaluable work for society. From a societal perspective, living alone is a very strong determinant 
of costs in dementia. The costs of living alone exceed those of permanent institutional care already 
at a moderate stage of dementia. In contrast, the costs of PWD living with a caregiver are far below 
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Table 1. Characteristics of participants according to their living status. 







Age, mean (SD) 83 (5) 78 (6) <0.001 
Women, n (%) 87 (82) 195 (38) <0.001 
Education 
   <8 years 
   8-12 years 










CDR, "personal care" 
  Fully capable of self-care 
  Needs prompting 
  Requires assistance in personal care 












Charlson comorbidity index, mean (SD) 2.7 (1.6) 2.3 (1.7) 0.012 
MMSE, mean (SD) 20.6 (3.8) 17.9 (6.5) <0.001 
Number of medications, mean (SD) 8.4 (3.1) 6.3 (3.2) <0.001 
 Antidementia medication, n (%)     
 ChEI, n (%) 










CDR, n (%) 
 0.5 very mild 
 1 mild 
 2 moderate 





















Caregivers' mean age (SD)  60 (11) 76 (7) <0.001 
Caregivers' sex: female, (%) 60 (68) 314 (62) 0.27 
Caregiver severely burdened1 (%) 12 (11) 49 (10) 0.60 
SD=standard deviation; CDR=Clinical Dementia Rating scale (Hughes et al. 1982); Charlson 
(Charlson et al. 1987); MMSE=Mini-Mental State Examination (Folstein et al. 1975); 
ChEI=Cholinesterase inhibitor; 1 Severely burdened= Zarit burden scale (Zarit et al. 1980) > 60 
points or ”Feels worn out all the time or most of the time for the past 4 weeks” (item from RAND-
36; Hays et al. 2001). 
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Table 2. Number and costs of services used by participants with dementia and costs of antidementia medications and lost productivity costs of 
caregivers and participants with dementia below retirement age during the two-year follow-up.  










Service Mean number of used services (SD)   Mean cost of services (SD) /pyrs 
Direct costs       
Medical costs       
Specialised hospital days 1.03 (0.26) 2.96 (0.44) 0.35 (0.20 to 0.61) 792 874 (224) 2785 (392) 
Emergency department visits 0.30 (0.05) 0.57 (0.04) 0.52 (0.49 to 0.65) 299 89 (15) 216 (19 ) 
Specialised ambulatory care 
visits 
1.26 (0.24) 0.64 (0.05) 1.99 (1.33 to 2.96) 283 357 (66) 194 (16) 
Subacute or rehabilitation 
hospital days 
21.53 (3.24) 7.73 (0.90) 2.48 (1.73 to 3.56) 252 5914 (940) 2682 (285) 
Visits to GP 0.93 (0.13) 2.03 (0.08) 0.46 (0.34 to 0.61) 119 110 (15) 246 (10) 
GP home visits 0.67 (0.06) 0.15 (0.02) 4.46 (3.10 to 6.40) 181 121 (12) 27 (4) 
Nurse visits 0.28 (0.05) 1.34 (0.08) 0.21 (0.14 to 0.31) 52 14 (3) 70 (5) 
Physiotherapy visits 0.33 (0.07) 1.53 (0.21) 0.22 (0.13 to 0.36) 124 41 (9) 187 (26) 
 Hospital at home days 0.20 (0.20) 0.05 (0.03) 4.12 (0.40 to 42.33) 241 48 (48) 13 (9) 










Table 2. Continued… 










     
Social care services       
Home care services, visits 423.68 (28.81) 26.29 (4.12) 16.12 (11.53 to 
22.52) 
45 31021 (1357) 6588 (410) 
Day care, days 94.98 (1.09) 15.79 (1.37) 6.02 (5.07 to 7.14) 104 9850 (124) 1625 (139) 
Respite care, days 10.30 (1.77) 18.23 (1.42) 0.57 (0.39 to 0.82) 199 2014 (344) 3751 (295) 
Social worker visits 0.03 (0.01) 0.32 (0.04) 0.11 (0.05 to 0.25) 166 6 (2) 55 (7) 
Nursing home days 46.88 (8.58 ) 22.34 (2.85) 2.10 (1.36 to 3.25) 141 6614 (1213) 3064 (387) 
Indirect costs       
Lost productivity costs1     3883 (359) 193 (52) 
Total costs     49156 (1763) 16416 (846) 
1 The cost of lost productivity was valued as the average wage in Finland (men 19.21€/h, women 16.45€/h) (Tilastokeskus 2019), and calculated 
for those below the average retirement age in Finland (men 61.6 years, women 60.9 years) (Kannisto 2019). The average ADL/IADL caregiving 







Figure 1. Age- and sex-adjusted costs of health and social care at various stages of dementia among 
those living alone versus those living with a caregiver. MMSE= Minimental State Examination 
(Folstein et al. 1975), CDR=Clinical Dementia Rating (Hughes et al. 1982), pyrs=person years.  
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